ASCO Annual Meeting | Conference

Genetic Testing Delivers Personalized Lung Cancer Therapy

June 5th 2011

Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer

NKTR-102 Shows Promise in Phase II Trial

June 5th 2011

Metastatic breast cancer patients with demonstrated disease progression after taxane therapy face an uphill battle in fighting their disease.

Circulating Tumor Cells Show Promise as Surrogate for Survival in Prostate Cancer Trials

June 5th 2011

Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.

Regional Radiation Therapy Improves Outcomes in Early Breast Cancer

June 5th 2011

Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence

Amonafide Plus Cytarabine Fails To Meet Primary Endpoint

June 4th 2011

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High-Dose Methotrexate Better for ALL

June 4th 2011

High doses of methotrexate increases EFS for children and young adults

Molecular Profiling Boosts Targeted Therapies in Phase I Trial

June 4th 2011

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

Dr. Joensuu on the Imatinib for High-Risk GIST Trial

June 4th 2011

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial

Tim Turnham Discusses Melanoma Treatment Advances

June 4th 2011

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Investors Taking Stock of Key ASCO Abstracts

May 19th 2011

Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting

Genetic Analysis Yields Biomarker for Neuropathy

May 18th 2011

A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy

Cabozantinib (XL184) Demonstrates Antitumor Activity and Reduces or Eliminates Bone Metastases in Multiple Cancers

May 18th 2011

Cabozantinib (XL184), an investigational oral tyrosine kinase inhibitor, demonstrated antitumor activity in multiple types of advanced solid tumors.

Study Results Show Ovarian Cancer Deaths Are Not Reduced by Early-Detection Screening Methods

May 18th 2011

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

Study Confirms Extending Testing to Every 3 Years in Women Who Test Negative for the HPV Virus

May 18th 2011

A large-scale study of HPV testing and Pap smear for cervical cancer screening confirms that women can safely extend screening intervals from 1 to 3 years.

PSA Found to Be Highly Predictive of Long-Term Risk of Death From Prostate Cancer

May 18th 2011

Prostate-specific antigen (PSA) levels can accurately predict the risk of developing metastasis or death from prostate cancer up to 30 years later

Among Women at High Risk for Breast Cancer, Study Finds Smoking, Not Moderate Alcohol Use, Increases Risk of Common Cancers

May 18th 2011

A prospective study analyzed the risk of contracting common cancers based on baseline self-reporting data on smoking, alcohol use, and physical activity

Stay tuned for Live Conference Coverage from ASCO 2011

May 18th 2011

ASCO 2011, June 3-7, 2011 McCormick Place, Chicago, IL

PREVIOUS PAGE